Login to Your Account

BI engages Arena in $262M GPCR deal for schizophrenia

By Karen Carey
Staff Writer

Wednesday, January 13, 2016

As mental illness continues to grow at alarming rates, causing severe economic and social burdens on society, Boehringer Ingelheim GmbH (BI) validated Arena Pharmaceuticals Inc.'s G protein-coupled receptors (GPCR) technology with an exclusive drug research collaboration focused initially on schizophrenia and worth a potential $262 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription